NCT03459443 - A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

March 29, 2021

Study Completion Date

March 29, 2021

Conditions

C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative GlomerulonephritisIC-MPGNDense Deposit Disease

Interventions

DRUG

Danicopan

Danicopan was to be administered as an oral tablet.

Trial Locations (13)

Clinical Study Site, Philadelphia

Clinical Study Site, Birmingham

Clinical Study Site, Columbus

Clinical Study Site, Cincinnati

Clinical Study Site, Stanford

Clinical Study Site, New Haven

Clinical Study Site, Sydney

Clinical Study Site, Brisbane

Clinical Study Site, Melbourne

Clinical Study Site, Antwerp

Clinical Study Site, Ranica

Clinical Study Site, Leiden

Clinical Study Site, Nijmegen